pipette
ENEnglish

Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study

D. Rhee, J. Lewis, T. De Francesco, K. Nelson, T. Ianchulev, S. R. Sarkisian

PreprintUso en el mundo real

En palabras de los autores

PurposeTo characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG). DesignProspective, multicenter real-world evidence study (CREST; NCT05506423). ParticipantsAdults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up. MethodsAdverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level. Main Outcome MeasuresPre-specified ocular safety endpoints: adverse events, clinically significant hypotony, sustained intraocular pressure (IOP) elevation [&ge;] 10 mmHg beyond 30 days, allograft migration, corneal endothelial decompensation, secondary incisional glaucoma surgery, and endothelial cell density. ResultsOf 395 eyes (mean age 72.8 years; 52% female), 267 were combined with phacoemulsification (Cohort 1) and 128 standalone (Cohort 2). Medicated IOP decreased from 19.1 to 14.5 mmHg (p < 0.001) and medications from 1.9 to 1.2, with 42% medication-free. Sustained IOP elevation occurred in 34 eyes (8.6%), BCVA loss [&ge;] 2 lines in 15 (3.8%), hyphema > 2 mm in 6 (1.5%) and hypotony in 1 (0.3%). Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. Serious events occurred in 12 eyes (3.0%). In the N=91 eyes with paired specular microscopy data, endothelial cell density changed -6.5% (-8.7%, -4.4%). There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia. ConclusionsThrough 12 months no endothelial decompensation, endophthalmitis or sympathetic ophthalmia occurred, and most events were self-limiting or medically managed. Endothelial cell loss tracked concurrent cataract surgery rather than the allograft, though that subgroup is small. Follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls. Trial RegistrationClinicalTrials.gov (NCT05506423.)

Resultado principalLimitación que admiten los autores

Apareció: miércoles, 18 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.12.26367928